In this video, IMF Chief Medical Officer Dr. Joseph Mikhael provides his overview of the top multiple myeloma research presented at ASCO 2018. He discusses these five key abstracts:
Dr. Mikhael explains that the bb2121 Bluebird Trial that administered CAR T-cells to heavily relapsed multiple myeloma patients is important because it demonstrates that myeloma patients can have sustained remissions, up to one year, after undergoing this therapy.
He also points to the PVd study, which compares the combination of pomalidomide + bortezomib + dexamethasone with pomalidomide + dexamethasone alone. This study shows that myeloma patients may benefit from pomalidomide treatment at the time of early relapse, and not just second or third relapse.
Dr. Mikhael comments that the ARROW study demonstrates that carfilzomib is more beneficial and easier to tolerate if it is administered once weekly, rather than two to three times weekly.
He also states that a newly tested combination of daratumumab + Kyprolis – at least early on its study – proves to be an effective myeloma therapy.
Finally, Dr. Mikhael discusses the combination of venentoclax + carfilzomib as possibly becoming a promising treatment for myeloma patients with t(11;14).